Regentis Biomaterials LTD F-1 registration statements

Regentis Biomaterials Ltd. has filed a registration statement for the resale of up to 3,807,143 ordinary shares by selling shareholders, following a private placement.

Regentis Biomaterials Ltd. has filed an amendment to its F-1 registration statement, primarily to update exhibits and the exhibit index.

Regentis Biomaterials Ltd. has filed a registration statement for a firm commitment offering of 3,333,334 ordinary shares to support clinical trials and operations.

Regentis Biomaterials Ltd. files an amended F-1 registration statement for its initial public offering, aiming to raise $9.1 million to advance its GelrinC knee cartilage repair product towards FDA approval and European commercialization.

Regentis Biomaterials, a regenerative medicine company, filed an F-1/A for its initial public offering, aiming to raise $9.1 million to fund pivotal trials and commercialization of its GelrinC knee cartilage repair product, despite a history of operating losses and a going concern warning.

Regentis Biomaterials Ltd. filed an amendment to its F-1 registration statement, updating auditor consent and providing extensive details on recent unregistered convertible and bridge loan agreements, including terms for IPO conversion and related party transactions.

Regentis Biomaterials Ltd., an Israeli regenerative medicine company, is seeking to raise approximately $9.1 million through an initial public offering to advance its lead product candidate, GelrinC, towards FDA approval for knee cartilage repair, despite a history of operating losses and a going concern qualification.

Regentis Biomaterials is seeking to raise capital through an initial public offering to advance its GelrinC cartilage repair technology.

Regentis Biomaterials plans to raise capital through a public offering of ordinary shares, aiming for a listing on the NYSE American.

Regentis Biomaterials is seeking to raise capital through an initial public offering to fund the development and commercialization of its GelrinC cartilage repair product.